Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 15 hours agoPfizer disclosed on May 7 that a child participating in another...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 12 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 21 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 19 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 13 hours agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 2 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 19 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 17 hours agoSarepta Therapeutics (NASDAQ:SRPT) stock rose over 3% Thursday after Pfizer (NYSE:PFE) announced...